SPTX — Seaport Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2042347 ·
Last close
$18.17
Market Cap
$972.65M
52W High
$28.38
52W Low
$14.85
ADV30
251,042
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -30,345,000 | -26,394,000 | 417,624,000 | 61,552,000 | 20,169,000 |
| Mar 2026 | 0 | — | -27,543,000 | -25,408,000 | 227,673,000 | 52,909,000 | 343,294,000 |
| Dec 2025 | 0 | — | -27,199,000 | -24,135,000 | 249,009,000 | 46,042,000 | 341,554,000 |
| Sep 2025 | 0 | — | -25,441,000 | -22,544,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-85,267,000
Investing CF
$90,713,000
Financing CF
$-1,753,000
CapEx
$-87,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.73
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-228,511,000
Inventory
—
Receivables
$4,723,000
ST Investments
$228,882,000
EBIT TTM
$-110,528,000
Pretax Income TTM
$-97,227,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -87,294,000 | -74,881,000 | 249,009,000 | 341,554,000 | -92,545,000 | -77,942,000 |
| Dec 2024 | 0 | -52,416,000 | -46,879,000 | 315,777,000 | 340,626,000 | -24,849,000 | -29,629,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$441,681,000
Forward EPS
$-2.39
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JBIO | Jade Biosciences, Inc. | $979.40M | $15.40 | — |
| MLTX | MoonLake Immunotherapeutics | $957.45M | $11.25 | — |
| SVRA | Savara Inc | $988.39M | $4.48 | — |
| ANRO | Alto Neuroscience, Inc. | $999.16M | $24.91 | — |
| CYRX | Cryoport, Inc. | $999.81M | $19.74 | — |
News headlines (Yahoo Finance, 1h cache)
How Much Upside is Left in Seaport Therapeutics, Inc (SPTX)? Wall Street Analysts Think 77.91%
2026-11-05 13:55 · Yahoo
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
2026-11-02 12:00 · Yahoo
Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference
2026-10-28 11:00 · Yahoo
Is Seaport Therapeutics (SPTX) Overvalued Based On Book Value?
2026-10-25 22:08 · Yahoo
Seaport Therapeutics (SPTX) Looks Cheap After Its Cash Runway Narrative Took Center Stage
2026-10-25 15:17 · Yahoo
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
2026-10-09 17:00 · Yahoo
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
2026-10-09 11:00 · Yahoo
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
2026-10-07 17:00 · Yahoo
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
2026-10-07 11:00 · Yahoo
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
2026-09-22 19:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.